- Home
- HE vs QURE Comparison
HE vs QURE Comparison
Compare HE & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | QURE |
|---|---|---|
| Founded | 1891 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | HE | QURE |
|---|---|---|
| Price | $11.87 | $20.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $11.50 | ★ $58.55 |
| AVG Volume (30 Days) | ★ 3.1M | 2.4M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $3,080,252,000.00 | $15,751,000.00 |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $2.10 | $158.05 |
| P/E Ratio | $134.67 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $8.14 | $7.76 |
| 52 Week High | $13.41 | $71.50 |
Technical Indicators
Market Signals| Indicator | HE | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 28.70 |
| Support Level | $11.56 | $20.55 |
| Resistance Level | $12.69 | $28.50 |
| Average True Range (ATR) | 0.39 | 1.35 |
| MACD | 0.04 | 0.23 |
| Stochastic Oscillator | 51.61 | 12.27 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.